Chemotherapy is the recommended option once hormonal therapy or vaccine becomes ineffective. First line treatment of Taxotere and cabazitaxel hs recently been approvd for second line. Several studies have found activity for Taxotere and carboplatin combinations.
The review by Oh et al concluded: “More recent Phase II studies of carboplatin suggested a moderate level of clinical and palliative activity when it was used as a single agent. However, when carboplatin was combined with a taxane and estramustine, high response rates were observed in several recent clinical trials. ….Several preliminary reports suggested that carboplatin and oxaliplatin may have activity as second-line chemotherapy. Platinum chemotherapy drugs historically have been considered inactive in HRPC, although a review of the data suggested otherwise. Carboplatin, in particular, induced very high response rates when it was combined with estramustine and a taxane, but it also appeared to have activity in patients who progressed after docetaxel.”
Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK; Prostate Cancer Clinical Trials Consortium.
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.Cancer. 2008 Feb 1;112(3):521-6.
Oh WK, Tay MH, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
Cancer. 2007 Feb 1;109(3):477-86.
MD Galsky et al, Docetaxel-based combination therapy for castration-resistant prostate cancer Ann Oncol (2010) 21 (11): 2135-2144.
Read the Layperson version here.